Drug Profile


Alternative Names: EphB4-HSA; EphB4-Human Serum Albumin; Human Serum Albumin-EphB4 conjugate; Recombinant EphB4-HSA Fusion Protein; Vas 01

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VasGene Therapeutics
  • Developer National Cancer Institute (USA); University of Southern California; VasGene Therapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action EphB4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Bladder cancer; Chronic myelomonocytic leukaemia; Head and neck cancer; Kaposi's sarcoma; Myelodysplastic syndromes; Non-small cell lung cancer; Solid tumours
  • Phase I Prostate cancer; Renal cancer

Most Recent Events

  • 15 May 2017 Phase-II clinical trials in Myelodysplastic syndromes (Combination Therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT03146871)
  • 20 Apr 2017 Phase-II clinical trials in Acute myeloid leukaemia (Combination Therapy) in USA (IV) (NCT03146871)
  • 20 Apr 2017 Phase-II clinical trials in Chronic Myelomonocytic leukaemia (Combination Therapy) in USA (IV) (NCT03146871)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top